Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Selinexor Efficacy and Safety Are Independent of Renal Function in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): A Post-Hoc Analysis from the Pivotal Phase 2b Sadal Study

Michael W. Schuster, MD, Miguel A Canales, MD PhD, Jason Westin, MD, Josée M Zijlstra, MD PhD, George A Follows, MD PhD, Reem Karmali, MDMSc, Nagesh Kalakonda, MD, Andre H. Goy, MD, Rene-Olivier Casasnovas, MD, Joost Vermaat, MD PhD, Eric Van Den Neste, MD, Sylvain Choquet, MD, Catherine Thieblemont, MD PhD, Federica Cavallo, MD PhD, Maria de Fatima De La Cruz, MD, Brian T. Hill, MD, Herve Tilly, MD PhD, Shireen Kassam, MBBS, FRCPath, PhD, Reda Bouabdallah, MD, Ulrich Jaeger, MD, Ronit Gurion, MD, Paolo Caimi, MD, Peter Martin, FRCPC, MD MS, Andrew Davies, MD PhD, Sonali M. Smith, MD, Graham P. Collins, MD DPhil, Fritz C. Offner, MD PhD, Gilles Salles, MD PhD, Xiwen Ma, Kelly Corona, Jean-Richard Saint-Martin, Anita A. Joshi, Kamal Chamoun, MD, Hongwei Wang, MD PhD, Jatin J. Shah, MD, Sharon Shacham, PhD MBA, Michael G Kauffman, MD PhD, Marie Maerevoet, MD

Blood (2020) 136 (Supplement 1): 34–35.

https://doi.org/10.1182/blood-2020-137025

Published: 2020

Journal Articles

Effect of Age on the Efficacy and Safety of Single Agent Oral Selinexor in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): A Post-Hoc Analysis of the Sadal Pivotal Study

Blood (2020) 136 (Supplement 1): 5–6.

https://doi.org/10.1182/blood-2020-137020

Published: 2020

Journal Articles

Selinexor in Combination with Pomalidomide and Dexamethasone (SPd) for Treatment of Patients with Relapsed Refractory Multiple Myeloma (RRMM)

Blood (2020) 136 (Supplement 1): 18–19.

https://doi.org/10.1182/blood-2020-139858

Published: 2020

Journal Articles

Eltanexor (KPT-8602), a Second-Generation Selective Inhibitor of Nuclear Export (SINE) Compound, in Patients with Higher-Risk Myelodysplastic Syndrome

Sangmin Lee, MD, Bhavana Bhatnagar, DO, Sanjay R Mohan, MD MSCI, William T. Senapedis, Jr., Erkan Baloglu, PhD, Hongwei Wang, MD, Jatin J. Shah, MD, Sharon Shacham, PhD MBA, Michael G. Kauffman, MD PhD

Blood (2019) 134 (Supplement_1): 2997.

https://doi.org/10.1182/blood-2019-124136

Published: 2019

Journal Articles

Preclinical Activity of IRAK4 Kinase Inhibitor CA-4948 Alone or in Combination with Targeted Therapies and Preliminary Phase 1 Clinical Results in Non-Hodgkin Lymphoma

Robert N Booher, PhD, Grzegorz S. Nowakowski, MD, Krish Patel, MD, Matthew A. Lunning, DO, Maria Elena S. Samson, B.S., Ruzanna Atoyan, MD, Anna W Ma, MS, Guang-Xin Xu, BS, Steven Dellarocca, B.S., Holly Modafferi, BS, Mylissa Borek, B.S., Zhidong Zhang, PhD, Jefferson Parker, PhD, Duncan Whitney, PhD, Hongwei Wang, MD, David P Tuck, MD, Anas Younes, MD

Blood (2018) 132 (Supplement 1): 4168.

https://doi.org/10.1182/blood-2018-99-117383

Published: 2018

Journal Articles

JQ1, a Selective Bromodomain Inhibitor, Augment the Immunogenicity of Mantle Cell Lymphoma By Influencing the Expression of PD-L1

Hongwei Wang, MD, Fengdong Cheng, MD, Jie Cheng, PhD, Alejandro Villagra, PhD, Jianguo Tao, MD PhD, James E. Bradner, MD, Eduardo M. Sotomayor, MD

Blood (2015) 126 (23): 822.

https://doi.org/10.1182/blood.V126.23.822.822

Published: 2015

Journal Articles

JQ 1, a Selective Bromodomain Inhibitor, Decreased the Expression of the Tolerogenic Molecule PDL1 in Antigen-Presenting Cells (APCs) and Restores the Responsiveness of Anergic CD4+ T Cells

Hongwei Wang, MD, Fengdong Cheng, MD, Limin Xing, MD, Xiaohong Zhao, PhD, Alejandro Villagra, PhD, Javier Pinilla-Ibarz, MD PhD, Jianguo Tao, MD PhD

Blood (2014) 124 (21): 2749.

https://doi.org/10.1182/blood.V124.21.2749.2749

Published: 2014

Journal Articles

Selective Inhibition of Histone Deacetylase 6 (HDAC6) and HDAC3 As a Novel Therapeutic Strategy in Mantle Cell Lymphoma (MCL)

Fengdong Cheng, MD, Bing Xia, MD, Eva Sahakian, PhD, Tint Lwin, MD PhD, Hongwei Wang, MD, Limin Xing, MD, Bijal D. Shah, MD, Patricio PerezVillarroel, BS, Maritza LienlafMoreno, BS, Yizhuo Zhang, MD, Steven N Quayle, PhD, Simon S Jones, PhD, Javier Pinilla-Ibarz, MD PhD, Alejandro Villagra, PhD, Eduardo M. Sotomayor, MD, Jianguo Tao, MD PhD

Blood (2014) 124 (21): 5397.

https://doi.org/10.1182/blood.V124.21.5397.5397

Published: 2014

Journal Articles

Histone Deacetylase 6 (HDAC6) Influences T-Cell Activation and Survival: Implications For Cancer Immunotherapy

Andressa Sodre Laino, M.S., David M Woods, Ph.D., Fengdong Cheng, MD, Hongwei Wang, MD, Eduardo M. Sotomayor, MD

Blood (2013) 122 (21): 1050.

https://doi.org/10.1182/blood.V122.21.1050.1050

Published: 2013

Journal Articles

Critical Role for Histone Deacetylase 6 (HDAC6) in the Regulation of IL-6, and the JAK/STA3 Signaling Cascade in Macrophages

Maritza Lienlaf, BS., Patricio Perez-Villarroel, BS., Fengdong Cheng, M.D., Hongwei Wang, MD, Danay Marante, MS, Sean Yoder, MS, Woan Karrune V., PhD, Tessa Knox, MS, Stephen Lagor, Javier Pinilla-Ibarz, MD, PhD, Edward Seto, PhD, Eduardo M. Sotomayor, MD, Alejandro Villagra, PhD

Blood (2012) 120 (21): 1039.

https://doi.org/10.1182/blood.V120.21.1039.1039

Published: 2012

Journal Articles

Inhibition of Histone Deacetylase 6 (HDAC6) Disrupts the Tolerogenic STAT3 Signaling Pathway and Augments Antitumor Immune Responses in Mantle Cell Lymphoma (MCL)

Hongwei Wang, MD, Fengdong Cheng, MD, Zi Wang, Maritza Lienlaf, BS., Patricio Perez-Villarroel, Tessa Knox, MS, Eva Sahakian, Ph.D, Javier Pinilla-Ibarz, MD, PhD, Pedro Horna, M.D., Selina Chen-Kiang, PhD, Peter Martin, MD, Joel Bergman, Alan Kozikowski, Alejandro Villagra, PhD, Jianguo Tao, MD, PhD, Bijal D. Shah, MD, Eduardo M. Sotomayor, MD

Blood (2012) 120 (21): 3724.

https://doi.org/10.1182/blood.V120.21.3724.3724

Published: 2012

Journal Articles

The Opposing Role of Histone Deacetylase 10 (HDAC10) and HDAC11 in Proliferation/Survival of Mantle Cell Lymphoma (MCL) and Chronic Lymphocytic Leukemia (CLL)

Eva Sahakian, Ph.D, Bijal D. Shah, MD, John Powers, B.S., Susan Deng, Oscar Merino, Ajaypal S. Gill, Jennifer Rock-Klotz, B.S., Karrune V. Woan, Lianet Vazquez, Hongwei Wang, MD, Selina Chen-Kiang, PhD, Jianguo Tao, MD, PhD, Alejandro Villagra, Javier Pinilla-Ibarz, MD, PhD, Eduardo M. Sotomayor

Blood (2011) 118 (21): 1363.

https://doi.org/10.1182/blood.V118.21.1363.1363

Published: 2011

Journal Articles

Enhancement of the Antigen-Presenting Cell Function of Mantle Cell Lymphomas (MCL) by Novel Molecularly Based Immunotherapeutic Strategies.

Hongwei Wang, MD, Fengdong Cheng, D. Noyes, K. Wright, S. Mohapatra, J. Tao, M. Schell, S. Sebti, M. Smith, K. Bhalla, J. Pinilla, S. Dessureault, D. Celis, E.M. Sotomayor, (Intr. by Eduardo M. Sotomayor)

Blood (2007) 110 (11): 2315.

https://doi.org/10.1182/blood.V110.11.2315.2315

Published: 2007

Journal Articles

A Novel Role of Histone Deacetylase 11 (HDAC11) in the Regulation of IL-10 Production and Immune Tolerance Mediated by Antigen-Presenting Cells.

Hongwei Wang, MD, Fengdong Cheng, M.D, D. Nguyen, M.D, I. Suarez, Phd, K. Wright, Phd, A.P. Atadja, Phd, E. Seto, Phd, K. Bhalla, M.D, A. Villagra, Phd, E.M. Sotomayor, M.D

Blood (2007) 110 (11): 1330.

https://doi.org/10.1182/blood.V110.11.1330.1330

Published: 2007

Journal Articles

The Immunomodulatory Drug Lenalidomide (CC5013; Revlimid), Enhances Antigen-Presenting Cell’s Function Leading to Effective Priming of CD4 + T-Lymphocytes.

Hongwei Wang, MD, Aung Naing, MD, Fengdong Cheng, MD, Pedro Horna, MD, Ildelfonso Suarez, PhD, Jason Brayer, PhD, Alan F. List, MD, Eduardo M. Sotomayor, MD

Blood (2005) 106 (11): 2391.

https://doi.org/10.1182/blood.V106.11.2391.2391

Published: 2005

Journal Articles

Treatment of Antigen-Presenting Cells with Histone Deacetylase Inhibitors Represents a Novel Strategy To Overcome CD4+ T-Cell Tolerance: Divergent Effects on the IL10 and IL-12 Promoter.

Hongwei Wang, MD, Fengdong Cheng, MD, P. Horna, MD, I.V. Suarez, PhD, Jian Wu, PhD, A.P. Atadja, PhD, E. Seto, PhD, K. Wright, PhD, K. Bhalla, MD, E.M. Sotomayor, MD

Blood (2005) 106 (11): 2392.

https://doi.org/10.1182/blood.V106.11.2392.2392

Published: 2005

Journal Articles

Cucurbitacins, a Family of Natural Compounds That Effectively Disrupt Stat3 Signaling in Antigen-Presenting Cells (APCs) Are Promising Agents To Overcome Tumor-Induced CD4+ T-Cell Tolerance.

Fengdong Cheng, MD, Hongwei Wang, MD, Alfonso Suarez, Pedro Horna, MD, Said Sebti, PhD, Eduardo M. Sotomayor, MD

Blood (2005) 106 (11): 1485.

https://doi.org/10.1182/blood.V106.11.1485.1485

Published: 2005

Journal Articles

Analysis of the Fate and Function of Antigen-Specific CD8 T Cells during B Cell Lymphoma Progression.

Jason Brayer, PhD, Fengdong Cheng, MD, Pedro Horna, MD, Ildefonso Suarez, BS, Hongwei Wang, MD, Eduardo M. Sotomayor, MD

Blood (2004) 104 (11): 80.

https://doi.org/10.1182/blood.V104.11.80.80

Published: 2004

NARROW

Selinexor Efficacy and Safety Are Independent of Renal Function in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): A Post-Hoc Analysis from the Pivotal Phase 2b Sadal Study

Effect of Age on the Efficacy and Safety of Single Agent Oral Selinexor in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): A Post-Hoc Analysis of the Sadal Pivotal Study

Selinexor in Combination with Pomalidomide and Dexamethasone (SPd) for Treatment of Patients with Relapsed Refractory Multiple Myeloma (RRMM)

Eltanexor (KPT-8602), a Second-Generation Selective Inhibitor of Nuclear Export (SINE) Compound, in Patients with Higher-Risk Myelodysplastic Syndrome

Preclinical Activity of IRAK4 Kinase Inhibitor CA-4948 Alone or in Combination with Targeted Therapies and Preliminary Phase 1 Clinical Results in Non-Hodgkin Lymphoma

JQ1, a Selective Bromodomain Inhibitor, Augment the Immunogenicity of Mantle Cell Lymphoma By Influencing the Expression of PD-L1

JQ 1, a Selective Bromodomain Inhibitor, Decreased the Expression of the Tolerogenic Molecule PDL1 in Antigen-Presenting Cells (APCs) and Restores the Responsiveness of Anergic CD4+ T Cells

Selective Inhibition of Histone Deacetylase 6 (HDAC6) and HDAC3 As a Novel Therapeutic Strategy in Mantle Cell Lymphoma (MCL)

Histone Deacetylase 6 (HDAC6) Influences T-Cell Activation and Survival: Implications For Cancer Immunotherapy

Critical Role for Histone Deacetylase 6 (HDAC6) in the Regulation of IL-6, and the JAK/STA3 Signaling Cascade in Macrophages

Inhibition of Histone Deacetylase 6 (HDAC6) Disrupts the Tolerogenic STAT3 Signaling Pathway and Augments Antitumor Immune Responses in Mantle Cell Lymphoma (MCL)

The Opposing Role of Histone Deacetylase 10 (HDAC10) and HDAC11 in Proliferation/Survival of Mantle Cell Lymphoma (MCL) and Chronic Lymphocytic Leukemia (CLL)

Enhancement of the Antigen-Presenting Cell Function of Mantle Cell Lymphomas (MCL) by Novel Molecularly Based Immunotherapeutic Strategies.

A Novel Role of Histone Deacetylase 11 (HDAC11) in the Regulation of IL-10 Production and Immune Tolerance Mediated by Antigen-Presenting Cells.

The Immunomodulatory Drug Lenalidomide (CC5013; Revlimid), Enhances Antigen-Presenting Cell’s Function Leading to Effective Priming of CD4 + T-Lymphocytes.

Treatment of Antigen-Presenting Cells with Histone Deacetylase Inhibitors Represents a Novel Strategy To Overcome CD4+ T-Cell Tolerance: Divergent Effects on the IL10 and IL-12 Promoter.

Cucurbitacins, a Family of Natural Compounds That Effectively Disrupt Stat3 Signaling in Antigen-Presenting Cells (APCs) Are Promising Agents To Overcome Tumor-Induced CD4+ T-Cell Tolerance.

Analysis of the Fate and Function of Antigen-Specific CD8 T Cells during B Cell Lymphoma Progression.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only